Nanfei Zou

This inventor holds 13 USPTO granted patents and 1 published patent application, plus 1 CIPO patent and 6 EPO patents. Top assignees: Celgene Corporation, Signal Pharmaceuticals, Inc., Schering Corporation. Active years: 2006-2024.

USPTO Granted Patents = 13 (Patent Applications = 1)

% Patents Active = 69.2

CIPO Patents = 1 (Patent Applications = 1)

EPO Patents = 6 (Patent Applications = 7)

Average Co-Inventor Count = 8.5

ph-index = 4

Forward Citations = 54(Granted Patents)

Location History:

Edison, NJ (US) (2006)
East Brunswick, NJ (US) (2010 - 2012)
Cranford, NJ (US) (2013 - 2019)
Fanwood, NJ (US) (2019 - 2024)

Company Filing History:

Signal Pharmaceuticals, Inc.

Merck Sharp + Dohme Corp.

patents

Years Active: 2006-2024

Loading Chart...

13 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12029738 - Antiproliferative compounds and methods of use thereof (2024-07-09),

2. 11185543 - Antiproliferative compounds and methods of use thereof (2021-11-30),

3. 10675281 - Antiproliferative compounds and methods of use thereof (2020-06-09),

4. 10590136 - Processes for the preparation of cis-4-[2-{[(3S,4R)-3-fluorooxan-4-yl]amino}-8-(2,4,6-trichloroanilino)-9H-purin-9-yl]-1-methylcyclohexane-1-carboxamide (2020-03-17),

5. 10517873 - Solid forms of 2-(tert-butylamino)-4-((1R,3R,4R)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide, compositions thereof and methods of their use (2019-12-31),

6. 10357489 - Antiproliferative compounds and methods of use thereof (2019-07-23),

7. 10226461 - Solid forms of 2-(tert-butylamino)-4-((1R,3R,4R)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide, compositions thereof and methods of their use (2019-03-12),

8. 9814713 - Solid forms of 2-(tert-butylamino)-4-((1R,3R,4R)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide, compositions thereof and methods of their use (2017-11-14),

9. 9365524 - Solid forms of 2-(tert-butylamino)-4-((1R,3R,4R)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide, compositions thereof and methods of their use (2016-06-14),

10. 8598343 - Process for preparing a 2-alkynyl substituted 5-amino-pyrazolo-[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine (2013-12-03),

11. 8198463 - Process for the preparation of 6,6-dimethyl-3-azabicyclo-[3.3.0]-hexane compounds and enantiomeric salts thereof (2012-06-12),

12. 7723531 - Process for the preparation of 6,6-dimethyl-3-azabicyclo-[3.1.0]-hexane compounds and enantiomeric salts thereof (2010-05-25),

13. 7049440 - Enantioselective process (2006-05-23),

Title: Nanfei Zou: Innovator in Antiproliferative Compounds

Introduction

Nanfei Zou is a prominent inventor based in Cranford, NJ (US), known for his significant contributions to the field of pharmaceuticals. He holds a total of 13 patents, showcasing his innovative approach to developing new compounds and methods for treating various medical conditions.

Latest Patents

Among his latest patents is a groundbreaking invention related to antiproliferative compounds and methods of use thereof. This patent details a specific compound, 4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-1-yl)-3-fluorobenzonitrile, which can be utilized in treating, preventing, or managing multiple myeloma. The patent also includes pharmaceutical compositions comprising these compounds and methods for their application.

Career Highlights

Nanfei Zou has worked with notable companies in the pharmaceutical industry, including Celgene Corporation and Signal Pharmaceuticals, Inc. His experience in these organizations has contributed to his expertise in drug development and innovation.

Collaborations

Throughout his career, Nanfei Zou has collaborated with esteemed colleagues such as Hon-Wah Man and Xiaoling Lu. These partnerships have further enhanced his research and development efforts in the pharmaceutical field.

Conclusion

Nanfei Zou's work in developing antiproliferative compounds has made a significant impact in the medical community. His innovative spirit and dedication to research continue to drive advancements in pharmaceutical science.